Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Tariff impact likely to be 'limited and manageable' - Senior

(Sharecast News) - Shares in Senior sparked on Thursday, after the high-tech engineering firm reiterated its full-year outlook and downplayed the impact of tariffs. Updating on the three months to March end, the FTSE 250 company said it had seen "robust" trading during the first quarter.

Group revenues rose 3% year-on-year, with aerospace sales up 4%, driven by growth in civil aviation.

Flexonics revenues were largely in line with the previous year, after lower sales to upstream oil and gas customers were largely offset by a strong performance in downstream oil and gas.

Overall, the book to bill ratio was 1.34, which Senior called "healthy".

Looking to the rest of the year, it acknowledged that the global tariff regime kick-started by Donald Trump could have a broad macroeconomic impact on the markets it operates in.

But it continued: "For Senior, the direct impact of announced tariffs is limited and manageable.

"Overall, the outlook for the full-year is unchanged. The board anticipates good growth in 2025, in line with expectations.

"We continue to expect Flexonics performance for the full-year to be broadly similar to 2024. Good growth is anticipated in aerospace, driven by increasing aircraft build rates, operational efficiency benefits and improved contract pricing, with the second half performance expected to be higher than the first half."

As at 0915 BST, shares in Senior were 3% stronger at 124.2p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.